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Abstract  22 
Objective: To evaluate the efficacy of pneumococcal vaccines concerning hospital or 23 
intensive care unit (ICU) admissions due to pneumonia after vaccination. 24 
Setting: Inpatient and ICUs at Hamad General Hospital.  25 
 Methods: The retrospective study included adults who were vaccinated between June 26 
2012 and June 2013. Patient records were reviewed for hospital or ICU admissions due to 27 
pneumonia two years before and after vaccination.  28 
Main outcomes measures: The primary outcome was to compare the rates of hospital and 29 
ICU admissions for pneumonia two years before and after vaccination. 30 
The secondary outcome was to evaluate the efficacy of pneumococcal vaccines against 31 
different comorbidities. 32 
Key findings: One hundred sixty-one patients were included with a dominant age group 33 
of 64–85 (52%) years old. Comorbidities reported were hypertension (HTN), diabetes 34 
mellitus (DM), chronic obstructive pulmonary disease (COPD) and asthma. The rate of 35 
hospital admission due to pneumonia was significantly reduced within two years after 36 
vaccination, 71% to 39% (p < 0.001). There was a trend toward reduced ICU admission 37 
(12.4% to 10.6), but the results did not achieve statistical significance (p>0.72).  38 
In diabetic, hypertensive and COPD/Asthma patients, there was a statistically significant 39 
reduction in hospitalization. Although there was a reduction in ICU admission for both 40 
commodities the results did not achieve statistical significance 41 
Conclusion: Adults who received pneumococcal vaccines experienced reduced rates of 42 
hospital versus ICU admissions due to pneumonia infection.  43 
44 
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INTRODUCATION  45 
Pneumococcal and influenza infection can cause significant morbidity and infection-46 
related mortality. In 2006, pneumonia and influenza together were ranked as the eighth 47 
leading cause of death in the United States of America (USA) (1). In 2006, 55,477 people 48 
died of pneumonia in the USA (2). Throughout the last decade direct and indirect costs 49 
for pneumococcal and influenza infections have been estimated to be in millions (1). 50 
Pneumonia has become a worldwide concern due to its high prevalence and impact on 51 
health care systems. Yearly in USA, pneumonia infection accounts for 500,000 case of 52 
respiratory tract infection (RTI), 50,000 cases of bacteremia, and 3,000 cases of 53 
meningitis (2). There were no exact epidemiological studies for pneumonia in Qatar. 54 
Pneumococcal vaccines recommended being administered in high-risk populations, such 55 
as elderly (over 65 years of age) and younger adults with underlying health problems 56 
such as chronic obstructive pulmonary disease (COPD), diabetes mellitus (DM), 57 
congestive heart failure (CHF), and sickle-cell anemia. Patients with diseases that impair 58 
the immune system (such as acquired immune deficiency syndrome AIDS) and those 59 
undergoing cancer therapy or organ transplantation, or patients with other chronic 60 
illnesses are particularly vulnerable and therefore need to be vaccinated (3). Besides, 61 
immunizing eligible patients with influenza and pneumococcal vaccines is considered an 62 
inpatient quality healthcare standard. Eventually, vaccination can help in prevention and 63 
diminish antibiotic resistance through its ability to reduce their use. Furthermore, 64 
pneumococcal vaccination and influenza vaccine was found to have a cardioprotective 65 
effect (4). Of note, the administration of the influenza vaccine showed an additive 66 
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protective impact regarding in-hospital mortality from pneumonia and cardiac failure 67 
among elderly patients (5).  68 
69 
More than 90% of all pneumococcal infections can be prevented by a single 70 
pneumococcal vaccine, which protects against 23 different types of streptococcus 71 
pneumonia (5). Approximately 50% of these deaths could be avoided through the use of 72 
the pneumococcal vaccine (6). Simonsen et al. suggested that patients over 18 years old 73 
are the age group with more than 90% of the benefit for vaccination regarding death and 74 
hospitalizations (7). 75 
On the other hand, a meta-analysis of 22 randomized and non-randomized clinical studies 76 
evaluating the efficacy of the pneumococcal polysaccharide vaccine showed that the 77 
vaccine doesn’t appear to be effective against pneumonia, even among the recommended 78 
population (8). 79 
A double-blind, randomized control, single-centre trial covering 84,496 patients 80 
randomly assigned to receive either the 13-valent polysaccharide pneumococcal vaccine 81 
or a placebo, with a four-year follow-up, showed a 45% reduction of vaccine-type 82 
community-acquired pneumonia (CAP) (p = 0.0006), a 45% reduction in non-83 
invasive/non-bacteremia CAP (p = 0.0067), and a 75% reduction in invasive vaccine-type 84 
pneumococcal disease. Additionally, the study emphasizes a favorable safety profile (1). 85 
There is a scarcity of data about the pneumococcal vaccine effectiveness amongst the 86 
Middle East and North Africa (MENA) region and particularly in Qatar. Hence, the 87 
vaccine effectiveness in term of hospitalization and ICU admission reduction was 88 
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evaluated amongst a group of patients who received the pneumococcal vaccine during the 89 
study period in a tertiary teaching hospital   90 
Aim of the study 91 
To evaluate the effectiveness of pneumococcal vaccines in reducing hospital and 92 
intensive care unit admissions due to pneumonia in immunized adult patients within two 93 
years of immunization compared with the cross-matched case group in age and 94 
comorbidities. 95 
Method 96 
Study design and setting.  97 
This retrospective study included all adult patients (18 years of age or older) who were 98 
admitted to the medical ward for any medical reason, and received a pneumococcal 99 
vaccine (Pneumococcal conjugate vaccine (PCV-13) and/or pneumococcal 100 
polysaccharide vaccine (PPV-23)) upon there discharge from Hamad General Hospital, 101 
Qatar, between June 2012 and June 2013.We excluded pregnant women, patients on 102 
dialysis and patients who had organ transplants mainly kidney or liver on regular immune 103 
suppressants.  Hamad General Hospital is a 603-bed tertiary care center that covers all 104 
specialties except for hematology, oncology, cardiology, and obstetrics. It has been 105 
accredited by Joint Commission International (JCI) since 2006. 106 
Source of information and data collection.  107 
Data were collected from a quality project done in Hamad General Hospital in 2012 and 108 
2013(9). The project aimed to estimate the rate of the hospital compliance with the 109 
recommendations from national and international guidelines, such as the Center for 110 
Disease Control and Prevention guidance (CDC). Followed by a retrospective chart 111 
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review for all hospital and ICU admissions two years before the vaccination year June 112 
2012 to June 2013( June 2010 to June 2012) and two years after ( June 2013to June 113 
2015). Data were secured in a particular form that included patient demographics, clinical 114 
characteristics, laboratory results, and outcomes. This study was approved by the Hamad 115 
General Hospital research committee as well as the Hamad Medical Corporation 116 
institutional review board (IRB), 117 
Diagnosis of Pneumonia was considered according to Physician’s notes, X-rays, 118 
microbiological results. Patients who had an admitting diagnosis of pneumonia with chest 119 
X-ray changes with or without microbiological results—were counted as a pneumonia-120 
related infection. 121 
Outcomes  122 
The primary outcome was an evaluation of the rate of hospital and ICUs admissions due 123 
to pneumonia. The secondary outcome was an evaluation of the effectiveness of 124 
pneumococcal vaccines amongst different comorbidities. 125 
Statistical analysis  126 
Data were analyzed descriptively using percentages, frequencies and means standard 127 
deviations for interval variables. Chi-square tests were performed to identify significant 128 
associations between pneumococcal vaccinations in medical ward and ICU hospital 129 
admissions. All analysis was conducted using SPSS.PASW. Statistical software version 130 
18.  131 
132 
Results 133 
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The study included 161 patients, of them 60% were male, and 52% were in the age group 134 
64-85 years old. Comorbidities included diabetes (57% of patients), hypertension (70%)135 
and COPD or asthma (45%) as displayed in (Table 1). The rate of hospital admission due 136 
to pneumonia was significantly reduced within two years after vaccination, from 71% to 137 
39% (p < 0.001), as illustrated in (Fig. 1). There was a trend towards reduced ICU 138 
admissions, (12.4% to 10.6%) but the results did not achieve statistical significance (p 139 
>0.72).140 
For the secondary outcomes, diabetic and hypertensive patients who were vaccinated had 141 
a statistically significant reduction in hospital admission after vaccination. Hospital 142 
admission dropped from 70.7% to 37.0% (p < 0.0001) for patients with diabetes and from 143 
71.7% to 39.8% (p < 0.0001) for those with hypertension. However, there was no 144 
statistically significant reduction in ICU admission—14.1% to 12% (p >0.824) and 145 
12.4% to 13.3% (p > 1.0) for diabetes and hypertension, respectively (Fig. 2). In patients 146 
who had asthma or COPD, vaccination did show significant reduction in hospital  but not 147 
in  ICU admissions 75.0% to 36.1% (p < 0.001) and 11.1% to 8.3% (p > 0.774), 148 
respectively. 149 
Table 1: Baseline Characteristics 
Gender 
Male 97 (60%) 
Female 64 (40%) 
Age Group 
Group 1 (18–40 yrs.) 16 (9.9%) 
Group 2 (41–63 yrs.) 35.4 (22.3%) 
Group 3 (64–85 yrs.) 84 (52.0%) 
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Fig. 1, Percentage of hospital and ICU admissions due to pneumonia 155 
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158 
159 
Fig. 2, Sub-group analysis of hospital and ICU admissions pre and post vaccination due 160 




The results of this study show that pneumococcal vaccines reduced hospital admissions 165 
among adults. It also shows some protection against hospital admissions for pneumonia 166 
with specific comorbidities. Our findings are supported by the recommendation of the 167 
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guidelines for the management of community-acquired pneumonia CAP in adults (10).In 169 
which those groups with similar comorbidities are eligible for pneumococcal vaccination. 170 
(10). Pilishvili et al. found that hospitalization notably declined in older adults (age >    171 
years old) where the disease burden from pneumonia was substantial and in-hospital 172 
mortality was estimated at up to 12% (11). 173 
The current study appears to be the first to evaluate and differentiate the vaccine 174 
effectiveness in regards to different hospital admissions (Hospital and ICU admissions).  175 
Pneumococcal vaccines showed a decreasing trend in ICU admissions related to 176 
pneumonia, but it was not statistically significant; however, this could be attributed to the 177 
small sample size. These results were consistent with a meta-analysis of 22 trials that 178 
included 101,507 participants, which found that vaccinations didn’t prevent death, 179 
pneumonia, or invasive pneumococcal infections. However, this meta-analysis did not 180 
take into consideration the rate of hospitalization (8). 181 
Ortqvist et al. conducted the first randomized control trial that evaluated the effectiveness 182 
of PPV-23 in preventing pneumonia in the elderly. This was a multicenter study that 183 
included 691 participants aged 50–85 years. Participants were randomized to receive 184 
PPV-23 or a placebo after being hospitalized for CAP and were followed up within 2.5 185 
years. In the vaccinated group, 19% developed pneumonia versus 16% in the placebo 186 
group. The relative risk for the placebo group was 0·83 (95% CI 0.58–1.12, p = 0.31). 187 
However, this study was underpowered, and the new recommendations came with the 188 
administration of PCV followed by PPV, or vice versa according to age and 189 
comorbidities (12,13). 190 
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Johnstone et al. followed up two thousand nine hundred fifty patients who received PPV 191 
while being admitted with CAP, for five years after discharge. In this population-based 192 
cohort study, Johnstone et al. did not find a significant reduction in either death or 193 
hospitalization with PPV. However, the inclusion of some co-infected pneumonia 194 
patients was considered as a study drawback 14).Despite being the first study to measure 195 
the vaccines’ efficacy on preventing ICU admission, the current study had several 196 
limitations. Neither the mortality cases that were admitted to the ICU due to pneumonia, 197 
nor the 28 days mortalities after ICU discharge were considered because the study was 198 
examining the risk and the probability of decreasing admission. It was challenging to 199 
include or consider cardiovascular patients in a subgroup analysis because those patients 200 
will be admitted to the heart hospital, which is a different facility with its ICU. Including 201 
patients vaccinated with pneumococcal and annual influenza vaccine is a significant 202 
limitation of this study. However, this was considered as the data collection was during 203 
the immunization season e. Differentiating and subgrouping the patients to further two 204 
groups according to each pneumococcal vaccine was hard to attempt, as the data was 205 
taken from a quality project that was done to ensure that eligible patients were 206 
vaccinated. The new recommendations are that each patient will receive the two types of 207 
vaccination but through different time intervals. Giving that our study proved that any of 208 
the pneumococcal vaccines had a protective role in regards to hospital admission. 209 
210 
In the findings for asthma and COPD one of the highest-risk groups for pneumonia 211 
infection and admissions, the vaccine showed an ability to protect and only reduce 212 
hospital and ICU admissions. Several explanations could be behind these findings; one of 213 
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the most cited reasons is the failure of the vaccine to maintain antibody response. Musher 214 
et al. studied participants who received PPV then PCV after six months (15), or vice-215 
versa. The patients’ immunoglobulin G (IgG) was measured at baseline, four to eight 216 
weeks, and six months after each vaccine. At six months, the IgG had returned to its 217 
original baseline levels, questioning the beneficial effect of pneumococcal vaccines in 218 
adults (15). 219 
Conclusion 220 
The pneumococcal vaccine is effective in reducing hospital admission amongst diabetic, 221 
hypertensive and COPD/Asthma patients, however the clinical significance of 222 
pneumococcal vaccines in decreasing hospital and ICU admissions as well as the age- 223 
specific concomitant comorbidities that will highly benefit from the vaccine and the 224 
timing of the booster doses must be determined in more extensive long-term clinical trials 225 
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